

# Gideon Hirschfield

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5619400/gideon-hirschfield-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296  
papers

21,437  
citations

62  
h-index

142  
g-index

330  
ext. papers

25,950  
ext. citations

9  
avg, IF

6.96  
L-index

#	Paper	IF	Citations
296	P066 Lower serum concentration of sulfated bile acids is associated with Primary Sclerosing Cholangitis Inflammatory Bowel Disease comorbidity and advanced liver fibrosis. <i>Journal of Crohn's and Colitis</i> , <b>2022</b> , 16, i173-i174	1.5	0
295	Elevated Serum Aminotransferases.. <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> , 327, 580-584	13.4	0
294	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	1
293	Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores. <i>European Radiology</i> , <b>2022</b> , 32, 67-77	8	1
292	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. <i>Efficacy and Mechanism Evaluation</i> , <b>2022</b> , 9, 1-54	1.7	0
291	A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
290	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study. <i>EBioMedicine</i> , <b>2022</b> , 80, 104068	8.8	1
289	Primary Biliary Cholangitis: Clinical Insights Into Diagnosis and Staging. <i>Gastroenterology and Hepatology</i> , <b>2021</b> , 17, 2-5	0.7	0
288	The Evolving Use of Biochemical Markers in the Management of Primary Biliary Cholangitis: Discussion. <i>Gastroenterology and Hepatology</i> , <b>2021</b> , 17, 14-17	0.7	0
287	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1688-1697.e14	6.9	5
286	Diagnosis and Management of Recurrent Autoimmune Liver Disease <b>2021</b> , 424-437		
285	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	31
284	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1514-1522	0.7	1
283	Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 689-698	6.1	0
282	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. <i>Hepatology</i> , <b>2021</b> , 74, 2307	11.2	1
281	The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis. <i>Hepatology</i> , <b>2021</b> , 74, 3269-3283	11.2	7
280	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. <i>JHEP Reports</i> , <b>2021</b> , 3, 100255	10.3	11

279	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1344-1354	13.4	16
278	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , <b>2021</b> , 160, 2483-2495.e26	13.3	9
277	A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 929-939	4.2	2
276	Recent advances in clinical practice: epidemiology of autoimmune liver diseases. <i>Gut</i> , <b>2021</b> , 70, 1989-2003	13.2	7
275	Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 768-776.e10	6.9	3
274	Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding. <i>Hepatology</i> , <b>2021</b> , 73, 1618-1620	11.2	1
273	Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1248-1257	6.9	6
272	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100191	10.3	6
271	Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2021</b> , 41, 535-544	7.9	3
270	Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100217	10.3	10
269	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 321-329	13.4	17
268	The Epidemiology of UK Autoimmune Liver Disease Varies With Geographic Latitude. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2587-2596	6.9	7
267	The evolving potential of precision medicine in the management of autoimmune liver disease <b>2021</b> , 135-167		1
266	Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1009-1020	6	6
265	Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2021</b> ,	7.9	7
264	Sex Disparity in Liver Transplant and Access to Living Donation. <i>JAMA Surgery</i> , <b>2021</b> , 156, 1010-1017	5.4	0
263	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 572-581	13.4	8
262	The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single-Center Analysis. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1733-1746	4.5	1

261	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 634-646	13.4	11
260	Primary biliary cholangitis. <i>Lancet, The</i> , <b>2020</b> , 396, 1915-1926	4.0	33
259	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. <i>Liver International</i> , <b>2020</b> , 40, 1121-1129	7.9	6
258	A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 94-101	13.4	57
257	Recurrent Autoimmune Liver Disease and Its Impact on Clinical Practice <b>2020</b> , 233-245		
256	The Role of Extrahepatic Autoimmunity in Autoimmune Liver Disease <b>2020</b> , 277-288		
255	Symptoms, Chronic Disease, and Patient Management <b>2020</b> , 289-300		
254	Environmental Exposure and Risk in Autoimmune Liver Diseases <b>2020</b> , 83-102		
253	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. <i>European Radiology</i> , <b>2020</b> , 30, 3735-3747	8	5
252	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1066-1074	0.7	31
251	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1332-1345	6	12
250	Recurrent Autoimmune Liver Disease and its Scientific Significance <b>2020</b> , 247-261		
249	Making Sense of Overlap and Crossover Syndromes <b>2020</b> , 263-275		
248	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. <i>Hepatology Communications</i> , <b>2020</b> , 4, 399-408	6	1
247	Letter: histology is relevant for risk stratification in primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 192-193	6.1	6
246	Primary Biliary Cholangitis <b>2020</b> , 123-141		0
245	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. <i>Journal of Crohn's and Colitis</i> , <b>2020</b> , 14, 935-947	1.5	36
244	Genetics and Risk of Autoimmune Liver Diseases <b>2020</b> , 47-64		

243	The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. <i>Clinical Liver Disease</i> , <b>2020</b> , 15, 110-114	2.2	12
242	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 559-565	13.4	21
241	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 33,	2.2	1
240	Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. <i>Gastroenterology</i> , <b>2020</b> , 159, 915-928	13.3	37
239	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , <b>2020</b> , 72, 1253-1266	11.2	15
238	Primary biliary cholangitis: pathogenesis and therapeutic opportunities. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 93-110	24.2	58
237	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. <i>Liver International</i> , <b>2020</b> , 40, 382-392	7.9	7
236	The 6 CB of primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1255-1256	13.4	1
235	A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 15308	4.9	13
234	Review article: pathophysiology and management of primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1150-1164	6.1	8
233	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 179-187.e6	6.9	24
232	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 34-48	7.3	23
231	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 684-692.e6	6.9	10
230	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , <b>2020</b> , 69, 1502-1509	19.2	13
229	CD80 on Human T Cells Is Associated With FoxP3 Expression and Supports Treg Homeostasis. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 577655	8.4	1
228	Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 575843	5.7	10
227	Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis. <i>JHEP Reports</i> , <b>2019</b> , 1, 286-296	10.3	20
226	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102328	15.5	45

225	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. <i>Gut</i> , <b>2019</b> , 68, 1356-1378	19.2	73
224	Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1379-1387.e3	6.9	16
223	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 445-453	18.8	73
222	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2076-2084.e2	6.9	27
221	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 357-365	13.4	80
220	Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. <i>Liver International</i> , <b>2019</b> , 39, 967-975	7.9	13
219	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. <i>Hepatology Communications</i> , <b>2019</b> , 3, 365-381	6	30
218	Liver disease in the young adult: the challenges and rewards. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 248-254	18.8	0
217	Autoimmune hepatitis and complexities in management. <i>Frontline Gastroenterology</i> , <b>2019</b> , 10, 77-87	2.6	3
216	Proximity to transplant center and outcome among liver transplant patients. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 208-220	8.7	19
215	Simple Magnetic Resonance Scores Associate With Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2785-2792.e3	6.9	14
214	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1127-1136	6.1	29
213	A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. <i>Gastroenterology and Hepatology</i> , <b>2019</b> , 15, 145-154	0.7	8
212	Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis) <b>2019</b> , 574-591		0
211	Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. <i>BMJ Open Gastroenterology</i> , <b>2019</b> , 6, e000226	3.9	1
210	Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. <i>EBioMedicine</i> , <b>2019</b> , 50, 3-4	8.8	9
209	Intrahepatic macrophage populations in the pathophysiology of primary sclerosing cholangitis. <i>JHEP Reports</i> , <b>2019</b> , 1, 369-376	10.3	8
208	Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group. <i>JHEP Reports</i> , <b>2019</b> , 1, 437-445	10.3	24

207	The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1878-1885	0.7	9
206	Response to "Is the hub-and-spoke model of care delivery a possible answer to geographical variation in liver transplant outcomes?". <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 1248-1249	8.7	
205	Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. <i>Hepatology</i> , <b>2019</b> , 69, 2120-2135	11.2	28
204	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 483-493	13.4	77
203	Grand round: Autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 773-784	13.4	23
202	Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines. <i>Frontline Gastroenterology</i> , <b>2019</b> , 10, 316-319	2.6	5
201	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , <b>2019</b> , 156, 96-107.e1	13.3	52
200	Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1213-1219	6.1	12
199	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. <i>Hepatology Communications</i> , <b>2018</b> , 2, 421-436	6	21
198	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 631-644	6.1	49
197	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. <i>Gut</i> , <b>2018</b> , 67, 1568-1594	19.2	122
196	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. <i>Gut</i> , <b>2018</b> , 67, 1135-1145	19.2	35
195	Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 278-287.e7	6.9	27
194	Genetic association studies and the risk factors for developing the "Immuno-bile-logic" disease primary biliary cholangitis. <i>Hepatology</i> , <b>2018</b> , 67, 1620-1622	11.2	3
193	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , <b>2018</b> , 67, 1890-1902	11.2	139
192	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 626-634	18.8	60
191	Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN- $\gamma$ -secreting cells. <i>Journal of Autoimmunity</i> , <b>2018</b> , 94, 143-155	15.5	25
190	Work in Progress: Drugs in Development. <i>Clinics in Liver Disease</i> , <b>2018</b> , 22, 501-515	4.6	1

189	Autoimmune Hepatitis and Overlap Syndromes <b>2018</b> , 355-379		
188	The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 322-332	6.1	19
187	Primary Biliary Cholangitis <b>2018</b> , 217-232		
186	Deciphering the biology of IgG4-related disease: specific antigens and disease?. <i>Gut</i> , <b>2018</b> , 67, 602-605	19.2	11
185	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 254-264	0.7	44
184	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , <b>2018</b> , 67, 1920-1930	11.2	35
183	Cellular and Molecular Mechanisms of Autoimmune Hepatitis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2018</b> , 13, 247-292	34	59
182	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , <b>2018</b> , 67, 1517-1524	19.2	28
181	Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease. <i>Hepatology Communications</i> , <b>2018</b> , 2, 956-967	6	6
180	The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. <i>PLoS Biology</i> , <b>2018</b> , 16, e2005046	9.7	43
179	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 951-960	6.1	20
178	Pathophysiology of primary biliary cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2018</b> , 34-35, 17-25	2.5	13
177	Multiparametric magnetic resonance imaging for quantitation of liver disease: a two-centre cross-sectional observational study. <i>Scientific Reports</i> , <b>2018</b> , 8, 9189	4.9	31
176	Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 76-78	24.2	16
175	The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. <i>Gut</i> , <b>2017</b> , 66, 386-388	19.2	91
174	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
173	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. <i>Lancet, The</i> , <b>2017</b> , 389, 1114-1123	4.0	110
172	Low-dose interleukin-2 promotes STAT-5 phosphorylation, T survival and CTLA-4-dependent function in autoimmune liver diseases. <i>Clinical and Experimental Immunology</i> , <b>2017</b> , 188, 394-411	6.2	42



171	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 145-172	13.4	512
170	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1265-1281	13.4	62
169	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , <b>2017</b> , 49, 588-608	3.4	94
168	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 549-558	13.4	138
167	Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>Digestive Diseases</i> , <b>2017</b> , 35, 267-274	3.2	19
166	In Vitro and Ex Vivo Models to Study T Cell Migration Through the Human Liver Parenchyma. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1591, 195-214	1.4	
165	Expert clinical management of autoimmune hepatitis in the real world. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 723-732	6.1	48
164	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 269-273 <sup>36.3</sup>	14.0	
163	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	78
162	Seladelpar (MBX-8025), a selective PPAR- $\delta$ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 716-726	18.8	81
161	Primary sclerosing cholangitis and the management of uncertainty and complexity. <i>Frontline Gastroenterology</i> , <b>2017</b> , 8, 260-266	2.6	5
160	Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. <i>Scientific Reports</i> , <b>2017</b> , 7, 7652	4.9	3
159	HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry. <i>Hla</i> , <b>2017</b> , 90, 228-233	1.9	3
158	Should we screen for cirrhosis?. <i>BMJ, The</i> , <b>2017</b> , 358, j3233	5.9	6
157	Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 2187-2192	9.5	29
156	Immunogenetics in primary sclerosing cholangitis. <i>Current Opinion in Gastroenterology</i> , <b>2017</b> , 33, 93-98	3	12
155	Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 957-965	13.4	24
154	Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol. <i>BMJ Open</i> , <b>2017</b> , 7, e015081	3	18

153	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , <b>2017</b> , 30, 239-259	4	15
152	Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 116-122	13.4	27
151	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , <b>2017</b> , 65, 907-919	11.2	50
150	Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. <i>Journal of Autoimmunity</i> , <b>2017</b> , 77, 45-54	15.5	29
149	Insights into the management of Wilson's disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2017</b> , 10, 889-905	4.7	29
148	Genetics of Primary Sclerosing Cholangitis <b>2017</b> , 99-110		
147	Autoimmune Hepatitis and Crossover Syndromes. <i>In Clinical Practice</i> , <b>2017</b> , 203-226	0	
146	Using GWAS to identify genetic predisposition in hepatic autoimmunity. <i>Journal of Autoimmunity</i> , <b>2016</b> , 66, 25-39	15.5	73
145	The gut microbiota and host health: a new clinical frontier. <i>Gut</i> , <b>2016</b> , 65, 330-9	19.2	1182
144	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 329-36	2.4	41
143	OX40, OX40L and Autoimmunity: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2016</b> , 50, 312-32	12.3	109
142	Post-prophylaxis <i>Toxoplasma chorioretinitis</i> following donor-recipient mismatched liver transplantation. <i>Transplant Infectious Disease</i> , <b>2016</b> , 18, 805-808	2.7	7
141	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 631-43	59.2	574
140	An overview of the diagnosis and management of immunoglobulin G4-related disease. <i>Cmaj</i> , <b>2016</b> , 188, 953-961	3.5	11
139	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 71	3	21
138	Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1190-1193	13.4	15
137	Reply. <i>Gastroenterology</i> , <b>2016</b> , 150, 1689-1690	13.3	
136	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , <b>2016</b> , 65, 321-9	19.2	107

135	Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1692-9	4	29
134	Obeticholic acid for the treatment of primary biliary cirrhosis. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 13-26	3.8	42
133	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. <i>Hepatology</i> , <b>2016</b> , 63, 644-59	11.2	43
132	The Immunogenetics of Autoimmune Cholestasis. <i>Clinics in Liver Disease</i> , <b>2016</b> , 20, 15-31	4.6	17
131	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1290-1300	9.5	65
130	Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 9966-9973	5.6	2
129	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. <i>Hepatology</i> , <b>2016</b> , 64, 189-99	11.2	81
128	The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. <i>Hepatology</i> , <b>2016</b> , 63, 930-50	11.2	184
127	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , <b>2016</b> , 63, 1357-67	11.2	94
126	High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. <i>Hepatology</i> , <b>2016</b> , 63, 1608-19	11.2	51
125	Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab. <i>Frontline Gastroenterology</i> , <b>2016</b> , 7, 271-274	2.6	4
124	Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion. <i>Frontline Gastroenterology</i> , <b>2016</b> , 7, 240-245	2.6	1
123	Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-)) knockout mice is strain specific. <i>Hepatology</i> , <b>2016</b> , 63, 346	11.2	2
122	Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. <i>Journal of Autoimmunity</i> , <b>2016</b> , 68, 98-104	15.5	53
121	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , <b>2016</b> , 168, 25-29	9	41
120	The Pathogenesis of Autoimmune Liver Disease. <i>Digestive Diseases</i> , <b>2016</b> , 34, 327-33	3.2	21
119	Mesenchymal stromal cells and liver fibrosis: a complicated relationship. <i>FASEB Journal</i> , <b>2016</b> , 30, 3905-3908	3.9	53
118	The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1039-1050	6.1	41

117	Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 43, 283-93	6.1	70
116	Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. <i>Liver International</i> , <b>2015</b> , 35, 642-51	7.9	48
115	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , <b>2015</b> , 6, 8019	17.4	185
114	The immunogenetics of primary biliary cirrhosis: A comprehensive review. <i>Journal of Autoimmunity</i> , <b>2015</b> , 64, 42-52	15.5	88
113	A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 41, 980-90	6.1	34
112	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , <b>2015</b> , 149, 1804-1812.e4	13.3	235
111	Making the most of new genetic risk factors - genetic and epigenetic fine mapping of causal autoimmune disease variants. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2015</b> , 39, 408-11	2.4	7
110	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 582-96	5.6	57
109	Unmet clinical need in autoimmune liver diseases. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 208-18	13.4	44
108	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , <b>2015</b> , 64, 948-56	19.2	90
107	Genetics in PBC: what do the "risk genes" teach us?. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2015</b> , 48, 176-81	12.3	20
106	Autoimmune hepatitis: an approach to disease understanding and management. <i>British Medical Bulletin</i> , <b>2015</b> , 114, 181-91	5.4	26
105	Primary biliary cirrhosis: Renaming primary biliary cirrhosis-clarity or confusion?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 678-9	24.2	8
104	Reply: To PMID 25160979. <i>Gastroenterology</i> , <b>2015</b> , 148, 860-1	13.3	
103	Reply: To PMID 25500425. <i>Gastroenterology</i> , <b>2015</b> , 149, 508-9	13.3	
102	Aspects of the Pathophysiology of Primary Biliary Cirrhosis. <i>Digestive Diseases</i> , <b>2015</b> , 33 Suppl 2, 102-8	3.2	6
101	Liver disease in the UK. <i>Lancet, The</i> , <b>2015</b> , 385, 503	4.0	4
100	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. <i>Gastroenterology</i> , <b>2015</b> , 148, 751-61.e8	13.3	381

99	Novel therapeutic targets in primary biliary cirrhosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 147-58	24.2	94
98	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. <i>Hepatology</i> , <b>2014</b> , 60, 931-40	11.2	72
97	Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. <i>Gastroenterology</i> , <b>2014</b> , 146, 430-41.e6	13.3	193
96	The evolution of cellular deficiency in GATA2 mutation. <i>Blood</i> , <b>2014</b> , 123, 863-74	2.2	153
95	Mechanisms of tissue injury in autoimmune liver diseases. <i>Seminars in Immunopathology</i> , <b>2014</b> , 36, 553-68	2	44
94	Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1179-1185.e1	6.9	44
93	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1249-58	13.4	92
92	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1290-303	13.4	96
91	Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. <i>Gastroenterology</i> , <b>2014</b> , 147, 221-232.e7	13.3	61
90	Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. <i>American Journal of Roentgenology</i> , <b>2014</b> , 202, 536-43	5.4	46
89	PR3-ANCA: a promising biomarker in primary sclerosing cholangitis (PSC). <i>PLoS ONE</i> , <b>2014</b> , 9, e112877	3.7	43
88	Frequency and significance of IgG4 immunohistochemical staining in liver explants from patients with primary sclerosing cholangitis. <i>International Journal of Experimental Pathology</i> , <b>2014</b> , 95, 209-15	2.8	19
87	A liver mass post-Fontan operation. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2014</b> , 107, 571-2	2.7	22
86	Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis". <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1445-6	13.4	
85	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , <b>2014</b> , 147, 1338-49.e5; quiz e15	13.3	265
84	Overlap syndrome: A real syndrome?. <i>Clinical Liver Disease</i> , <b>2014</b> , 3, 43-47	2.2	7
83	Genetics of autoimmune liver disease: a brief summary for clinicians. <i>Digestive Diseases</i> , <b>2014</b> , 32, e1-6	3.2	3
82	The Diagnosis and Classification of Immune-Mediated Biliary Diseases <b>2014</b> , 111-122		

81	The role of attachment style and depression in patients with hepatitis C. <i>Journal of Clinical Psychology in Medical Settings</i> , <b>2013</b> , 20, 227-33	2	6
80	Genetic determinants of cholestasis. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 147-59	4.6	16
79	The genetics of complex cholestatic disorders. <i>Gastroenterology</i> , <b>2013</b> , 144, 1357-74	13.3	111
78	Primary sclerosing cholangitis. <i>Lancet, The</i> , <b>2013</b> , 382, 1587-99	40	370
77	Secondary Sclerosing Cholangitis <b>2013</b> , 123-133		
76	IgG4 related disease - a retrospective descriptive study highlighting Canadian experiences in diagnosis and management. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 168	3	18
75	Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 186-9	13.4	25
74	A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 327-35	13.4	28
73	The immunobiology and pathophysiology of primary biliary cirrhosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2013</b> , 8, 303-30	34	208
72	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , <b>2013</b> , 45, 670-5	36.3	267
71	The phenotypic expression of inflammatory bowel disease in patients with primary sclerosing cholangitis differs in the distribution of colitis. <i>Digestive Diseases and Sciences</i> , <b>2013</b> , 58, 2608-14	4	51
70	Treatment of autoimmune liver disease: current and future therapeutic options. <i>Therapeutic Advances in Chronic Disease</i> , <b>2013</b> , 4, 119-41	4.9	34
69	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , <b>2013</b> , 14, 179-86	4.4	44
68	Genetics of Primary Biliary Cirrhosis <b>2013</b> ,		3
67	Review article: overlap syndromes and autoimmune liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 36, 517-33	6.1	89
66	Patients with autoimmune hepatitis who have antimitochondrial antibodies need long-term follow-up to detect late development of primary biliary cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2012</b> , 10, 682-4	6.9	25
65	Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 1299-304	13.4	36
64	Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 333-9		12

63	Management of primary sclerosing cholangitis: conventions and controversies. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 261-8		10
62	Overlap Syndromes <b>2012</b> , 782-789		
61	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , <b>2012</b> , 55, 1495-506	11.2	24
60	Biliary atresia and survival into adulthood without transplantation: a collaborative multicentre clinic review. <i>Liver International</i> , <b>2012</b> , 32, 510-8	7.9	30
59	Prevalence and risk factors for liver biochemical abnormalities in Canadian patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 254-61	4.1	24
58	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , <b>2012</b> , 21, 5209-21	5.6	122
57	NOTCH2 mutations in Alagille syndrome. <i>Journal of Medical Genetics</i> , <b>2012</b> , 49, 138-44	5.8	152
56	The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 56-63	0.7	45
55	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. <i>Genes and Immunity</i> , <b>2012</b> , 13, 328-35	4.4	67
54	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. <i>Nature Genetics</i> , <b>2011</b> , 43, 1131-8	36.3	415
53	Diagnosis of primary biliary cirrhosis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 701-12	2.5	28
52	Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 374-85	13.4	356
51	A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. <i>Psychosomatics</i> , <b>2011</b> , 52, 433-40	2.6	15
50	Autoimmune Hepatitis and Overlap Syndromes <b>2011</b> , 452-477		1
49	Progress in the genetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , <b>2011</b> , 31, 147-56	7.3	57
48	IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. <i>Radiographics</i> , <b>2011</b> , 31, 1379-402	5.4	152
47	Primary biliary cirrhosis: one disease with many faces. <i>Israel Medical Association Journal</i> , <b>2011</b> , 13, 55-9	0.9	23
46	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , <b>2010</b> , 42, 658-60	36.3	337

45	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. <i>Nature Genetics</i> , <b>2010</b> , 42, 655-7	36.3	186
44	Autoantibodies and liver disease: uses and abuses. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2010</b> , 24, 225-31		42
43	Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2186-94	0.7	213
42	Navigating the road to personalized medicine: can we believe?. <i>Cmaj</i> , <b>2010</b> , 182, 651-2	3.5	1
41	Pathogenesis of cholestatic liver disease and therapeutic approaches. <i>Gastroenterology</i> , <b>2010</b> , 139, 1481-96	19.5	179
40	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , <b>2010</b> , 35, 436-42	15.5	103
39	Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. <i>Hepatology</i> , <b>2010</b> , 52, 223-9	11.2	35
38	The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. <i>Hepatology</i> , <b>2010</b> , 52, 562-70	11.2	36
37	A massive haematemesis. <i>BMJ, The</i> , <b>2010</b> , 340, b5534	5.9	
36	Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap. <i>Gut</i> , <b>2009</b> , 58, 152-3	19.2	11
35	Current status of therapy in autoimmune liver disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2009</b> , 2, 11-28	4.7	5
34	Adult liver transplantation: what non-specialists need to know. <i>BMJ, The</i> , <b>2009</b> , 338, b1670	5.9	14
33	Managing hepatitis C virus infection. <i>BMJ, The</i> , <b>2009</b> , 338, b2366	5.9	9
32	Autoimmune liver disease for the non-specialist. <i>BMJ, The</i> , <b>2009</b> , 339, b3305	5.9	11
31	Hepatocellular carcinoma for the non-specialist. <i>BMJ, The</i> , <b>2009</b> , 339, b5039	5.9	17
30	CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 931-7		61
29	Metagenomics and autoimmune liver disease: searching for the unknown. <i>Liver International</i> , <b>2009</b> , 29, 319-20	7.9	
28	Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2544-55	59.2	494



27	Cholestasis and cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2009</b> , 25, 175-9	3	18
26	Preventative hepatology: minimising symptoms and optimising care. <i>Liver International</i> , <b>2008</b> , 28, 922-34	7.9	13
25	Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE <sup>-/-</sup> mice. <i>Atherosclerosis</i> , <b>2008</b> , 196, 248-255	3.1	87
24	New insights into autoimmune liver diseases. <i>Hepatology Research</i> , <b>2008</b> , 38, 745-61	5.1	15
23	Antimitochondrial antibody-negative primary biliary cirrhosis. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 323-31; viii-ix	4.6	22
22	Primary biliary cirrhosis: the future. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 473-9; xi	4.6	1
21	The genetic study of primary biliary cirrhosis: great hope, some caution. <i>Current Gastroenterology Reports</i> , <b>2008</b> , 10, 187-9	5	
20	Fatal reactivation of hepatitis B after chemotherapy for lymphoma. <i>BMJ, The</i> , <b>2008</b> , 337, a423	5.9	19
19	Gilbert's syndrome: an overview for clinical biochemists. <i>Annals of Clinical Biochemistry</i> , <b>2006</b> , 43, 340-3	2.2	34
18	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , <b>2006</b> , 440, 1217-21	50.4	525
17	Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. <i>Circulation</i> , <b>2005</b> , 111, 1530-6	16.7	150
16	Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 8309-14	11.5	172
15	C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1387-97	59.2	2317
14	Amyloidosis: a clinico-pathophysiological synopsis. <i>Seminars in Cell and Developmental Biology</i> , <b>2004</b> , 15, 39-44	7.5	30
13	Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. <i>American Heart Journal</i> , <b>2004</b> , 147, 1071-7	4.9	32
12	Human C-reactive protein does not protect against acute lipopolysaccharide challenge in mice. <i>Journal of Immunology</i> , <b>2003</b> , 171, 6046-51	5.3	31
11	C-reactive protein and cardiovascular disease: new insights from an old molecule. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2003</b> , 96, 793-807	2.7	173
10	Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms. <i>Clinical Science</i> , <b>2003</b> , 104, 65P-66P		1

9	Evaluation of Bacterial Dna Probe Analysis in Valvular Heart Disease. <i>Clinical Science</i> , <b>2003</b> , 104, 4P-4P		
8	Amyloidosis: new strategies for treatment. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2003</b> , 35, 1608-13	5.6	44
7	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1805-12	15.9	1134
6	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 111, 1805-1812	15.9	2388
5	Recipient HLA-DR3, tumour necrosis factor-alpha promoter allele-2 (tumour necrosis factor-2) and cytomegalovirus infection are interrelated risk factors for chronic rejection of liver grafts. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 711-5	13.4	28
4	Autoimmune Hepatitis in Adults and Children281-296		
3	Wilson Disease: When Should you Think of Wilson Disease?352-366		0
2	Chronic Cholestatic Liver Disease and its Management in Adults and Children297-314		
1	Proceeding: Single Topic Conference in Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> ,e20210006	0.3	